21st Annual Update in Pulmonary Hypertension

This live CME/CNE accredited activity is the only New England symposium that illustrates novel pathways implicated in the pathogenesis of pulmonary vascular disorders and provides state of the art therapeutic approaches to the management of pulmonary hypertension. This education is accomplished via a combination of didactic lectures, case-based plenary and breakout discussions that feature leading experts as presenters and panelists. All presentations will be based on current evidence-based guidelines, research, and patient-centered outcomes.

Educational Outcome

This CE activity offers new and experienced healthcare providers state of the art education, recent data, case discussions, and practical guidance on the optimal screening and management of patients who have or are suspected of having pulmonary hypertension. It is expected that learners will utilize this education to make more informed treatment decisions that will measurably improve patient outcomes.

Objectives

After completing this activity, the participant should be better able to:

• Evaluate novel clinical trial designs and pathways being developed to improve treatment outcomes
• Examine clinical trial evidence on the safety and efficacy of current and emerging drug treatment options for PAH/PH
• Compare and contrast different PH Risk Scores and how they can be used not only to assess risk but also as an outcome for trials
• Consider consensus and controversies from the 7th World Symposium on Pulmonary Hypertension; how we can apply them (or not)
• Discuss cases illustrating the challenges of managing Pulmonary Vascular Disease associated with Liver Disease, CTEPH, and complex/rare cases in PH
• Explain the pathophysiology of PH-ILD as well as current treatment options and ongoing clinical trials
• Provide guidance on how to use and incorporate new advanced therapeutic agents into clinical practice

Target Audience

This activity is intended for physicians (pulmonologists, cardiologists, rheumatologists and general practitioners), fellows, residents, nurse practitioners, registered nurses and other healthcare practitioners engaged in the care of patients with pulmonary arterial hypertension.

Supporters/Exhibitors

The conference directors and planning committee would like to offer a special thank you to our 2024 exhibitors.

DIAMOND

Gossamer Bio
Johnson & Johnson
Keros Therapeutics
Merck & Co., Inc.
United Therapeutics Corporation

PLATINUM

Insmed
Liquidia

GOLD

Pulmovant

BRONZE

Accredo Health
AstraZeneca
Bayer U.S. Healthcare
Boehringer Ingelheim
CVS Specialty Pharmacy
Regeneron

PATIENT ADVOCACY ORGANIZATIONS

Pulmonary Hypertension Association
Team PHenomenal Hope

NON-EXHIBITING SUPPORTERS

Respira Therapeutics
TotalCME